---
document_datetime: 2025-02-20 08:48:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/qaialdo-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: qaialdo-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 0.9649859
conversion_datetime: 2025-12-26 19:06:33.082129
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Qaialdo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|--------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2780/ 202403   | Periodic Safety Update EU Single assessment - spironolactone | 14/11/2024                          | 13/01/2025                                  | SmPC and Labelling               | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2780/202403. |

<!-- image -->

<!-- image -->